Talaris has raised $150m in an initial public offering almost two decades after being spun out of University of Louisville as Regenerx.
Talaris Therapeutics, a US-based cell therapy developer spun out of University of Louisville, has priced its shares at $17 each and raised $150m in its initial public offering.
The company will trade on the Nasdaq Global Select Market under the ticker symbol TALS, having issued more than 8.8 million shares.
Founded in 2002 as Regenerex, Talaris is working on cell therapies that help prevent the rejection of transplanted organs and eliminate the need for immunosuppressants. Its lead…
